Cytokinetics, Inc. (CYTK) Posts Q4 Loss of 16c/Share; Guides FY12 Revs
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $77.74 +2.16%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
JAGX, CLIR, ZTO, More
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
JAGX, CLIR, ZTO, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q4 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $757 thousand versus the consensus estimate of $5.62 million.
Sees FY12 revenue of $4-$5 million, versus the consensus of $4 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Sees FY12 revenue of $4-$5 million, versus the consensus of $4 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c
- Analog Devices climbs as fiscal Q3 results, Q4 outlook beat forecasts
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
